Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099333 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00099333 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 49 participants.
The verdict
NCT00099333, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).
Interventions
- DRUG Insulin
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2004-02 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099333
The ClinicalTrials.gov registry entry for NCT00099333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin is the first listed.
NCT00099333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099333 about?
NCT00099333 is a clinical study titled "Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents". This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).
What is the current status of trial NCT00099333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2004-02. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00099333?
The interventions under investigation include: Insulin (DRUG), exenatide (DRUG).
Who is sponsoring clinical trial NCT00099333?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.